Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients;El Péptido-1 Exógeno Similar a Glucagón para la Hiperglucemia en Pacientes Gravemente Enfermos

Annals of Pharmacotherapy

Volumn 46, Issue 1, 2012, Pages 124-129

  Pinelli, Nicole R ^a   Jones, Mathew C ^b   Monday, Lea M ^c   Smith, Zachary ^d   Rhoney, Denise H ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

^d HENRY FORD HOSPITAL   (United States)

Author keywords

Blood glucose; Critical care; Glucagon like peptide 1; Hyperglycemia

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PLACEBO;

ACUTE DISEASE; AREA UNDER THE CURVE; CRITICAL ILLNESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; NAUSEA; PRIORITY JOURNAL; REVIEW; VOMITING;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; CRITICAL CARE; CRITICAL ILLNESS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 84855646428     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q417     Document Type: Review

References (20)

1. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001;17:107-24.
2. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
3. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009;180:821-7.
4. van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.
5. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
6. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006;105:244-52.
7. Dossett LA, Cao H, Mowery NT, Dortch MJ, Morris JM Jr, May AK. Blood glucose variability is associated with mortality in the surgical intensive care unit. Am Surg 2008;74:679-85; discussion 685.
8. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-36.
9. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-403.
10. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-31.
11. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998;21:1925-31.
12. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001;24:720-5.
13. Nauck MA, Walberg I, Vethacke A, et al. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004;118:89-97.
14. Meier JJ, Weyhe D, Michaely M, et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004;32:848-51.
15. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;100:824-9.
16. Müssig K, Oncü A, Lindauer P, et al. Effects of intravenous glucagonlike peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008;102:646-7.
17. Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009;13:R67.
18. Deane AM, Summers MJ, Zaknic AV, et al. Exogenous glucagon-like peptide-1 attenuates the glycemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care 2011;15:R35.
19. Deane AM, Chapman MJ, Fraser RJ, et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 2010;38:1261-9.
20. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5.